





PHARMACEUTICAL 2023

IVERIC bio Inc.
Rank 115 of 446



The relative strengths and weaknesses of IVERIC bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IVERIC bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 115% points. The greatest weakness of IVERIC bio Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 184%, being 141% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	662,826
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	35,587
Liabilities, Non-Current	96,579
Other Assets	3,051
Other Compr. Net Income	-139
Other Expenses	0
Other Liabilities	0
Other Net Income	4,695
Other Revenues	0
Property and Equipment	946
Research and Development	117,012
Selling, General and Administrative Expense	72,894

Output Variable	Value in 1000 USD
Assets	666,823
Liabilities	132,166
Expenses	189,906
Revenues	0
Stockholders Equity	534,657
Net Income	-185,211
Comprehensive Net Income	-185,280
Economic Capital Ratio	184%